Showing 1 - 5 results of 5 for search 'Chris J O’Callaghan', query time: 0.04s Refine Results
  1. 1
    Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial

    Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial by Jiahui Zhang, Weili Kong, Pingzhao Hu, Derek Jonker, Malcolm Moore, Jolie Ringash, Jeremy Shapiro, John Zalcberg, John Simes, Dongsheng Tu, Chris J. O'Callaghan, Geoffrey Liu, Wei Xu

    Published 2023-03-01
    Get full text
    Article
  2. 2
    Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer

    Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer by Jodi I. Rattner, Karen A. Kopciuk, Hans J. Vogel, Patricia A. Tang, Jeremy D. Shapiro, Dongsheng Tu, Derek J. Jonker, Lillian L. Siu, Chris J. O'Callaghan, Oliver F. Bathe

    Published 2023-08-01
    Get full text
    Article
  3. 3
    Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

    Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer by Daniel Shepshelovich, Amanda R. Townsend, Osvaldo Espin‐Garcia, Lidija Latifovic, Chris J. O’Callaghan, Derek J. Jonker, Dongsheng Tu, Eric Chen, Eric Morgen, Timothy J. Price, Jeremy Shapiro, Lillian L. Siu, Michiaki Kubo, Alexander Dobrovic, Mark J. Ratain, Wei Xu, Taisei Mushiroda, Geoffrey Liu

    Published 2018-11-01
    Get full text
    Article
  4. 4
    Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer

    Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer by Mélina Boutin, James T. Topham, Harriet Feilotter, Hagen F. Kennecke, Félix Couture, Mohammed Harb, Peter Kavan, Scott Berry, Howard J. Lim, John R. Goffin, Chaudhary Ahmad, Anthony Lott, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen, Jonathan M. Loree

    Published 2023-06-01
    Get full text
    Article
  5. 5
    The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

    The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma by Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, James T. Topham, Petr Kavan, Derek Jonker, Stephen Welch, Felix Couture, Frederic Lemay, Mustapha Tehfe, Mohammed Harb, Nathalie Aucoin, Yoo-Joung Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, Christina A. Kim, Pan Du, Shidong Jia, David F. Schaeffer, Sharlene Gill, Dongsheng Tu, Chris J O’Callaghan

    Published 2022-08-01
    Get full text
    Article

Search Tools: